Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Interventions: 1 cycle is 28days. Nintedanib (150mg or 200mg) is orally administered twice daily and TAS-102 (35mg/m2) is orally administered twice daily in 1-5days and 8-12 days Primary outcome(s): 16 weeks progression free survival rate ( 16W PFS rate) Study Design: Single arm Non-randomized干预方案：每个治疗周期为28天。尼达尼布（Nintedanib）150mg或200mg每日两次口服给药；TAS-102 35mg/m²于第1~5天及第8~12天每日两次口服给药。 主要研究终点：16周无进展生存率（16W PFS率） 研究设计：单臂非随机试验